Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aquila Biopharmaceuticals Inc.

Division of Agenus Inc.

Latest From Aquila Biopharmaceuticals Inc.

Agenus Teams Up With NewVac On Russian Deal

The Massachusetts biotech has found a partner to commercialize its cancer vaccine in Russia and develop the drug for other indications.

BioPharmaceutical Europe

Biotech Private Premiums

Contrary to assumptions, public biotech companies can actually sell their equity privately at premiums to their 3-month average trading price. As for illiquidity, the bane of the biotech investor: it may actually help some companies increase their offering prices.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Cambridge Biotech Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Agenus Inc.
  • Senior Management
  • Allison Taunton-Rigby, PhD, Pres. & CEO
    James Warren, VP, Fin., Treas. & CFO
    Gerald Beltz, PhD, SVP, R&D
    Eileen J Heffernan, Sr. Dir., Bus.Dev.
  • Contact Info
  • Aquila Biopharmaceuticals Inc.
    Phone: (508) 628-0100
    175 Crossing Blvd.
    Framingham, MA 01702